

# S2408 Pre-launch Meeting

*S2408: A Randomized Phase III Multicenter Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula*

**THURSDAY, APRIL 4 • 2 – 3 PM PT • BECKLER ROOM (302), LEVEL 3**

*The S2408 pre-launch meeting will introduce participants to this recently approved phase III multicenter trial for patients undergoing distal pancreatectomy for cancer or a pre-malignant pancreatic lesion*

**STUDY CHAIR:**



Jonathan Sham, MD, MBEE

**CO-CHAIR:**



Venu Pillarisetty, MD

**SPONSORING COMMITTEE CHAIR:**



Robert Krouse, MD

**SURGERY COMMITTEE CHAIRS:**



Syed Ahmad, MD



Flavio Rocha, MD

S2408 was recently approved by the NCI's Division of Cancer Prevention to evaluate whether a single dose of the somatostatin analogue *lanreotide* may prevent the "Achilles Heel" of pancreatic surgery – postoperative pancreatic fistula (POPF). POPF delays chemotherapy, increases healthcare costs, and decreases survival.

**THE SESSION WILL REVIEW:**



Trial background, eligibility criteria and treatment plan



Placebo plan (a SWOG-first!)



Biospecimen collection



Patient reported outcomes

*Surgeons, medical oncologists, and oncology research professionals are encouraged to attend and learn more about this unique SWOG trial!*

**ATTEND IN-PERSON OR VIRTUALLY.**